

Rogers, GB and Van Der Gast, CJ and Serisier, DJ (2014) *Predominant pathogen competition and core microbiota divergence in chronic airway infection.* ISME Journal, 9. pp. 217-225. ISSN 1751-7362

Downloaded from: http://e-space.mmu.ac.uk/621055/ Publisher: Nature Publishing Group DOI: https://doi.org/10.1038/ismej.2014.124

Please cite the published version

https://e-space.mmu.ac.uk

1	Predominant pathogen competition and core microbiota divergence in chronic airway infection
2	
3	
4	Geraint B Rogers ^{1,2*} , Christopher J van der Gast ³ , David J Serisier ^{2,4}
5	
6	¹ SAHMRI Infection and Immunity Theme, School of Medicine, Flinders University, Adelaide, Australia
7	² Immunity, Infection, and Inflammation Program, Mater Research Institute, University of Queensland,
8	and Translational Research Institute, Woolloongabba, Queensland, Australia
9	³ NERC Centre for Ecology and Hydrology, Wallingford, OX10 8BB, UK
10	⁴ Department of Respiratory Medicine, Mater Adult Hospital, South Brisbane, Australia
11	
12	* For correspondence, E-mail: geraint.rogers@sahmri.com
13	
14	Running title: Pathogen dominance in bronchiectasis microbiota
15	
16	Keywords: chronic infection /microbiota divergence /respiratory microbiome /competitive exclusion
17	/commonness and rarity /interspecific competition
18	
19	Subject category: Microbial population and community ecology
20	
21	
22	
23	
24	
25	
26	
27	

28 Abstract

29	Chronic bacterial lung infections associated with non-cystic fibrosis bronchiectasis represent a
30	substantial and growing healthcare burden. Where Pseudomonas aeruginosa is the numerically
31	dominant species within these infections, prognosis is significantly worse. However, in many
32	individuals, Haemophilus influenzae predominates, a scenario associated with less severe disease.
33	The mechanisms that determine which pathogen is most abundant are not known.
34	We hypothesised that the distribution of H. influenzae and P. aeruginosa would be consistent with
35	strong interspecific competition effects. Further, we hypothesised that where P. aeruginosa is
36	predominant, it is associated with a distinct 'accessory microbiota' that reflects a significant interaction
37	between this pathogen and the wider bacterial community. To test these hypotheses, we analysed
38	16S rRNA gene pyrosequencing data generated previously from 60 adult bronchiectasis patients,
39	whose airway microbiota was dominated by either P. aeruginosa or H. influenzae. The relative
40	abundances of the two dominant species in their respective groups were not significantly different, and
41	when present in the opposite pathogen group the two species were found to be in very low
42	abundance, if at all. These findings are consistent with strong competition effects, moving towards
43	competitive exclusion. Ordination analysis indicated that the distribution of the core microbiota
44	associated with each pathogen, readjusted after removal of the dominant species, was significantly
45	divergent (ANOSIM, R = 0.07, P = 0.019). Taken together, these findings suggest that both
46	interspecific competition and also direct and/or indirect interactions between the predominant species
47	and the wider bacterial community, may contribute to the predominance of P. aeruginosa in a subset
48	of bronchiectasis lung infections.
49	
50	
51	
52	
53	
54	
55	

56 Introduction

57 The World Health Organization has reported that the global burden of diseases is shifting from 58 communicable to non-communicable diseases, with chronic conditions such as heart disease, strokes, 59 and lung diseases now being the chief causes of morbidity and mortality (Lopez et al., 2006). Among 60 the great challenges in studying the causes and treatment of chronic lung infections, is a consequence 61 of Koch's postulates and the subsequent concept of infection pathogenesis summarized by the 62 expression 'one microbe, one disease' (Nelson et al., 2013). Koch's postulates have shaped our 63 understanding of medical microbiology, as many important microbial diseases conform to them. 64 However, that orthodoxy is being undermined by a growing recognition that diverse important 65 diseases, including chronic lung infections, have a polymicrobial aetiology. This expanding 66 understanding of chronic polymicrobial infections, originating from studies of cystic fibrosis airway 67 microbiota, is beginning to be translated to other chronic lower respiratory diseases, including non-68 cystic fibrosis bronchiectasis (hereafter referred to as bronchiectasis).

69 Bronchiectasis is a chronic airway disease characterised by abnormal destruction and dilation 70 of the large airways, bronchi and bronchioles (Cohen and Sahn, 1999). It is associated with chronic 71 and frequently purulent expectoration, multiple exacerbations, and progressive dyspnoea that can 72 become disabling (Ellis et al., 1981; Cohen and Sahn, 1999; Barker, 2002), and represents a 73 substantial and growing healthcare burden. A recent US study demonstrated a marked increased 74 prevalence in older populations varying from 4.2/100000 adults aged 18-34 years to 271.8/100000 75 aged ≥ 75 years (Weycker et al., 2005). Bronchiectasis often goes unrecognized or is misdiagnosed 76 as asthma or chronic obstructive pulmonary disease (COPD), leading to an underestimated 77 prevalence. Despite this, bronchiectasis is associated with substantial socioeconomic cost due to the 78 frequent use of primary and secondary healthcare resources. An US epidemiological study of 79 bronchiectasis-associated hospitalizations from 1993 to 2006 demonstrated an average annual 80 hospitalization rate of 16.5/100000 population with a significant annual increase of 2.4% in men and 81 3.0% in women (Seitz et al., 2010), with the cost of managing bronchiectasis appearing to be rising 82 (Joish et al., 2013).

Airway inflammation resulting from chronic bacterial infection is thought to be a significant contributory factor driving disease progression in bronchiectasis (Barker, 2002). The perceived importance of bacterial pathogens in airway disease progression is reflected in the use of antibiotics

86 (Serisier and Martin, 2011; Serisier et al., 2013a), both as maintenance therapy, and to treat episodes 87 of acute exacerbation. However, our understanding of the mechanisms that underpin relationships 88 between infection by particular bacterial taxa and clinical outcomes is currently poor. This situation 89 undermines the development of rationales for the selection of particular antibiotic treatment regimes 90 (Serisier, 2012) or potentially specific anti-inflammatory therapy (Visser et al, 2012), and achieving 91 better insight into the manner in which treatments achieve beneficial outcomes. While bronchiectasis 92 can result from a variety of recognised aetiologies, it is often considered idiopathic. Recent studies 93 have revealed a substantial and diverse bacterial microbiota (Rogers et al., 2013b; Tunney et al., 94 2013; Rogers et al., 2014; van der Gast et al., 2014), which are typically dominated by either 95 Haemophilus influenzae or Pseudomonas aeruginosa. Perhaps unsurprisingly given its colonisation of 96 the upper airways in healthy individuals, *H. influenzae* is detectable in lower airway secretions from 97 almost all bronchiectasis patients and is commonly the numerically dominant species (Rogers et al., 98 2013b; Rogers et al., 2014). In contrast, P. aeruginosa dominated infections occur in a smaller number 99 of patients (Rogers et al., 2014), but, are associated with an accelerated decline in lung function, more 100 frequent pulmonary exacerbations, greater sputum production, and a higher requirement for antibiotic 101 therapy (Evans et al., 1996; Ho et al., 1998; Shoemark et al., 2007; Rogers et al., 2014).

102 A better understanding of the way in which P. aeruginosa interacts with the airway 103 environment could provide important mechanistic insights into chronic infection in this patient group 104 and in chronic respiratory infections more widely. Both the physiochemical characteristics of the airway 105 environment, and the composition of the pre-existing lung microbiota, are likely to influence the 106 likelihood of P. aeruginosa infection (Rogers et al., 2013a). Further, where P. aeruginosa dominates 107 the infection microbiota, its growth is likely to further affect the composition of airway environment. 108 This impact of colonisation could occur both directly through the metabolomic (Kozlowska et al., 2013) 109 and secretomic (Bergamini et al., 2012) footprint of P. aeruginosa, and, in turn, indirectly by 110 stimulating changes in the host immune response (Bergamini et al., 2012) and the activity of other co-111 colonising species (Bakkal et al., 2010; Tashiro et al., 2013). Whilst the causality in these interactions 112 is difficult to demonstrate, were such relationships to exist, they would result in both an association 113 between P. aeruginosa infection and measures of airway disease, and an association between P. 114 aeruginosa infection and microbiota composition. The first of these associations has been well 115 documented. However, to our knowledge, there have been no investigations to assess the second.

116 We hypothesised that (1) the distribution of H. influenzae and P. aeruginosa in airways 117 samples would be consistent with strong interspecific competition effects; i.e. when H. influenzae is 118 the dominant species in a bronchiectasis lung infection, the population size of P. aeruginosa will be 119 negatively impacted and vice versa when P. aeruginosa is dominant. (2) Where P. aeruginosa or H. 120 influenzae is dominant species in a bronchiectasis lung infection, they are associated with distinct 121 'accessory microbiota' that reflect a significant interaction between these pathogens and the wider 122 bacterial community. To test these hypotheses, we analysed 16S rRNA gene pyrosequencing data, 123 generated previously, from 60 adult bronchiectasis patients whose airway microbiota was dominated 124 by either P. aeruginosa or H. influenzae. H. influenzae-dominated infections were chosen as a 125 comparator group as they had been shown previously not to differ significantly in total bacterial load, 126 dominant taxon relative abundance, or prior antibiotic burden (intravenous, oral, and combined), with 127 those where P. aeruginosa was dominant (Rogers et al., 2014). Further, despite differences in disease 128 course, these patients did not differ significantly in serum C-reactive protein (CRP) levels, or sputum 129 IL-8 and IL-1β levels (Rogers et al., 2014) common markers of systemic and airway inflammation. To 130 limit the potential effect of antibiotic therapy to influence microbiota composition (Serisier, 2013b), a 131 sample set was chosen where there had been a four week period of clinical stability prior to collection, 132 with no supplemental antibiotics administered (Serisier et al., 2013c).

133

134 Materials and methods

The analysis performed here was based on 16S ribosomal RNA gene pyrosequencing data generated from induced sputum samples from adult patients with bronchiectasis, as part of the BLESS trial (Serisier *et al.*, 2013c). These data are available through the Sequence Read Archive (http://www.ncbi.nlm.nih.gov/sra) under the accession number SRP0356. Details of patient recruitment, sample collection, nucleic acid extraction, PCR amplification pyrosequencing, and bioinformatics processing have been published previously (Rogers *et al.*, 2013b; Serisier *et al.*, 2013c; Rogers *et al.*, 2014) and details of these processes are provided here as Supplementary Methods.

Of the 96 samples previously analysed, 26 were *P. aeruginosa*-dominated and 34 were *H. influenzae*-dominated. It is these 60 samples on which the analysis presented here is based. Patient details for these patients are shown in Table 1. As described previously, the species-level identification of *P. aeruginosa* and *H. influenzae* two species was confirmed using specific PCR-based

assays in all instances (Supplementary Methods), with identification by pyrosequencing treated as
 presumptive. Where species-level identities were not corroborated by specific assays, identities are
 presented at the genus level.

149 Bacterial taxa within each metacommunity were partitioned into core and satellite groups using the 150 Poisson distribution test as previously described (van der Gast et al., 2011; Rogers et al., 2013c). 151 One-way analysis of variance (ANOVA), regression analysis, coefficients of determination (r^2) , 152 residuals and significance (P) were calculated using Minitab software (version 16, Minitab, University 153 Park, PA, USA) as described previously (van der Gast et al., 2011; Rogers et al., 2013c). Canonical 154 correspondence analysis (CCA), analysis of similarity (ANOSIM), similarity of percentages (SIMPER) 155 analysis were performed using the PAST (Palaeontological Statistics, version 2.17) program available 156 from the University of Oslo website link (http://folk.uio.no/ohammer/ past) run by Øyvind Hammer. 157 Mann Whitney tests were performed using GraphPad Prism (version 5.01, La Jolla, CA 92037 USA). 158 Where predominant taxa were removed prior to analysis, the remaining relative abundance measures 159 were rescaled and expressed as percentages.

160

161 Results and Discussion

162 P. aeruginosa and H. influenzae share certain similarities, for example, they are both Gram 163 negative, rod-shaped, facultative anaerobic Gammaproteobacteria. However, these common 164 opportunistic pathogens are associated with very different clinical courses when dominant in 165 bronchiectasis lung infections. Here the relative abundances of the two predominant species in their 166 respective groups were high and not significantly different (ANOVA, $F_{1,58}$ = 0.096, P = 0.758; P. 167 aeruginosa mean abundance and standard deviation = $87.3 \pm 13.4\%$ and H. influenzae = $86.0 \pm$ 168 17.9%) (Fig. 1). When present in the opposite dominated group the two species were found to be in 169 only very low abundances (*P. aeruginosa* = $0.37 \pm 1.3\%$ and *H. influenzae* = $0.56 \pm 0.77\%$; ANOVA, 170 $F_{1.58}$ = 0.436, P = 0.511). Furthermore, P. aeruginosa was not detected in 12 from 34 samples of the 171 H. influenzae group, and 2 from 26 for H. influenzae in the P. aeruginosa group (Fig. 1). This is 172 consistent with strong competition effects between the two species, moving towards competitive 173 exclusion of the inferior competitor species; and more so for P. aeruginosa within the H. influenzae 174 group. If these patterns of dominance and suppression could be purely explained by the process of 175 interspecies competition then no between group differences in accessory microbiota would be

expected. However, the analyses performed here demonstrate that taxa present in the microbiota
associated with *P. aeruginosa* and *H. influenzae* predominance are significantly divergent.

178 The distribution of the two sets of microbiota, as determined by direct ordination using Bray-179 Curtis similarity measures, is shown in Fig. 2. Where the dominant taxa (P. aeruginosa or H. 180 influenzae) were included (Fig. 2a), divergence in the distribution of the microbiota was pronounced 181 and statistically significant (ANOSIM, R = 1, P < 0.0001). However, given the high proportion of total 182 bacterial abundance that these predominant taxa would account for within the microbiota (Fig. 1), 183 much of the variation between the two groups will result from their inclusion in the analysis. In order to 184 assess whether accessory microbiota composition differed significantly between the two groups, the 185 predominant taxa were removed and the relative abundances of the remaining taxa redistributed and 186 expressed as percentages. When subjected to ordination analysis, the distribution of the accessory 187 microbiota composition (Fig. 1b) were not found to be significantly divergent (ANOSM, R = 0.036, P =188 0.11).

189 Many accessory microbiota taxa are of low relative abundance. The potential contribution to 190 accessory microbiota of transient bacterial populations within the airways, as opposed to populations 191 of chronically infective bacteria, is therefore high. In order to reduce the effect of these satellite taxa, 192 the core microbiota (composed of non-randomly distributed taxa) in each of the two groups was 193 determined (Fig. 3). This is an approach that has been applied successfully in the analysis of chronic 194 bacterial infections associated with cystic fibrosis (van der Gast et al., 2011; Rogers et al., 2013a). In 195 the Haemophilus-dominated group, 9 of the 92 taxa detected were classified as core and 83 as 196 satellite, and in the Pseudomonas-dominated group, 8 of the 70 taxa detected were classified as core 197 and 62 as satellite. In each case, the contribution of individual taxa to the core microbiota was 198 assessed by SIMPER analysis (Tables 2 & S1). Ordination analysis was then performed using the 199 core taxa, and again the difference between the distribution of the core microbiota that included the 200 predominant *P. aeruginosa* and *H. influenzae* populations was significant (ANOSM, R = 1, P < 0.0001) 201 (Fig.4a). Moreover, the divergence in the distribution of the core microbiota, readjusted after removal 202 of the dominant species, was also found to be significantly divergent (ANOSIM, R = 0.07, P = 0.019) 203 (Fig. 4b). Satellite taxa were not significantly different between the groups (ANOSIM, R = 0.05, P =204 0.06).

205 To assess whether significant differences existed in the relative abundances of specific core 206 taxa between the P. aeruginosa- and H. influenzae-dominated samples, Mann-Whitney tests were 207 used and performed on readjusted core taxa abundance data after P. aeruginosa and H. Influenzae 208 are removed. This process identified *Prevotella* spp. and *Flavobacterium* spp. as being significantly 209 more abundant in the *P. aeruginosa*-dominated samples (P < 0.0001 and P = 0.003, respectively), 210 while Neisseria spp. was significantly more abundant in H. influenzae-dominated samples (P < P211 0.0001). Flavobacterium is a genera that has been reported previously to contribute to bacterial 212 communities present in chronic lung infections (Rogers et al., 2003; Rogers et al., 2004; van der Gast 213 et al., 2011; Rogers et al., 2013a) although typically present at low relative abundances. In contrast, 214 Prevotella spp. have been reported as both common, and often at high abundance in both 215 bronchiectasis and CF lung infections (Tunney et al., 2008; Field et al., 2010; Stressmann et al., 216 2012), and otitis media (Brook, 2008). Prevotella spp. appear to be particularly prevalent when co-217 colonising with P. aeruginosa, a factor that has led to the previous suggestion that a synergistic 218 relationship exists between P. aeruginosa and members of this genus (Su and Hassett, 2012). The 219 genus Prevotella is composed of species that are obligate anaerobes. While P. aeruginosa and H. 220 influenzae are both capable of fermentation and growth under anaerobic conditions (Schobert and 221 Jahn, 2010; Langereis and Hermans, 2013), the contributions of thick mucoid secretions that P. 222 aeruginosa can produce in the airways (Ma et al., 2012), a trait not demonstrated by H. influenzae 223 (Langereis and Hermans, 2013), may contribute to reduced oxygen permeation, leading to the 224 creation of greater opportunities for the growth of strict anaerobes, such as Prevotella spp. This model 225 would be consistent with the association observed here between H. influenzae and Neisseria, a genus 226 of typically aerobic species.

227 Canonical correspondence analysis was performed next to assess the extent to which 228 variance in the microbiota distribution can be accounted for by variation in measures of disease 229 severity, the presence of comorbidities, and non-antibiotic therapies. The results of these analyses are 230 shown in Table 3, and additionally superimposed onto Figs 2 & 4. In keeping with previous reports 231 (Rogers et al., 2014), the presence of P. aeruginosa in samples as the predominant taxon was 232 associated with high pulmonary exacerbation frequency and poor lung function (low FEV₁ percent 233 predicted), with these factors varying significantly with microbiota distribution. However, whilst such 234 clinical measures are associated with the presence of *P. aeruginosa*, these analyses also show that a significant relationship exists with the wider airway microbiota; a significant relationship was identified
here between the variance in core taxa and Leicester Cough Score (a measure of cough symptom
severity).

238 Here we observed distributions of predominant taxa consistent with strong interspecific 239 competition, supporting competitive exclusion in some instances. But we also observed, for instance, 240 that where P. aeruginosa is the numerically dominant species in a bronchiectasis lung infection it is 241 associated with a distinct accessory microbiota; suggesting in addition to interspecific competition 242 there are also direct and/or indirect interactions between the predominant species and the core 243 microbiota. To some extent, such an effect was also observed for H. influenzae, but was far less 244 pronounced. However, several different models could explain such interactions. For example, the 245 predominant species could influence the accessory microbiota composition through modification of the 246 airway environment and alteration of its selective properties (and vice versa); here, perhaps the fact 247 that H. influenzae is a common resident of the upper airways means that its presence is less 248 disruptive to the commonly occurring infective lower airway microbiota. Alternatively, the same change 249 in the characteristics of the airway could occur through intermediary interaction with the host that 250 results in an altered inflammatory profile, airway secretion composition, or secretion clearance rate. 251 Here, a wide array of virulence factors and pro-inflammatory traits possessed by P. aeruginosa 252 (Sadikot et al., 2005) may contribute to the magnitude of the effect of its predominance on the 253 accessory airway microbiota. Finally, external influences, such as antibiotic therapy, are likely to 254 contribute to selective pressures in the airway environment. While there was no significant difference 255 in historical antibiotic burden in the H .influenzae- and P. aeruginosa-dominated groups, the 256 contribution of more subtle differences in treatment history cannot be excluded. We suggest that no 257 single process is responsible for the associations observed, and rather a dynamic interaction between 258 many different factors give rise to the various types of microbiological scenario seen in vivo. The 259 potential complexity of these interactions makes their elucidation challenging. However, discerning 260 their basis is important given that a number of important clinical questions arise from the findings we 261 present here. These questions include; (1) Could accessory microbiota composition predict 262 subsequent P. aeruginosa predominance and its associated poor prognosis? (2) Could intervention 263 aimed at altering the characteristics of the airway environment, or the composition of the accessory 264 microbiota, reduce the likelihood of P. aeruginosa infection and predominance? (3) What are the

265 mechanisms to promote the dominance of *H. influenzae,* and as a consequence competitively exclude 266 or suppress *P. aeruginosa*?

267 In each case, addressing these questions will require in vitro competition experiments 268 between the two dominant bacterial species and members of the core microbiota that we have 269 identified as having likely interactions with P. aeruginosa and H. influenzae. In addition, longitudinal 270 sample sets that span both clinically and microbiologically important time periods will allow us to better 271 understand the in vivo mechanisms that lead to predominance of H. influenzae or P. aeruginosa and 272 its associated worse clinical outcomes. However, obtaining informative longitudinal sample sets in 273 adult bronchiectasis has significant challenges. Intensive, long-term sample collection would be 274 required to span rare and unpredictable events, such as the acquisition of *P. aeruginosa* in a condition 275 that has relatively slow progression (Martínez-García et al., 2007) and is commonly idiopathic (Anwar 276 et al., 2013). Given their potential to provide mechanistic insight into the relationship between 277 recognised airway pathogens, the wider airway microbiota, host immunity, and clinical outcome, such 278 long-term frequent sample collection represents an important next step.

In conclusion, we present evidence supporting the contribution of both interspecific competition, and direct and/or indirect interaction between predominant infective taxa and the wider bacterial community, to determining whether *H. influenzae* or *P. aeruginosa* dominates the chronic lung infections associate with bronchiectasis. Given the prognostic implications of *P. aeruginosa* dominance, these findings provide a basis for identifying the mechanisms that underpin this airway microbial ecology, and perhaps offering novel therapeutic opportunities.

- 285
- 286
- 287

288 Acknowledgements

289 This study was supported by the Mater Adult Respiratory Research Trust Fund.

290

291 Conflicts of interest

292 The authors declare no conflict of interest.

293

294 Supplementary information is available at ISMEJ's website

296	References
297	Anwar, G.A., McDonnell, M.J., Worthy, S.A., Bourke, S.C., Afolabi, G., Lordan, J. et al. (2013)
298	Phenotyping adults with non-cystic fibrosis bronchiectasis: a prospective observational cohort study.
299	<i>Respir Med</i> 107: 1001-1007.
300	
301	Bakkal, S., Robinson, S.M., Ordonez, C.L., Waltz, D.A., and Riley, M.A. (2010) Role of bacteriocins in
302	mediating interactions of bacterial isolates taken from cystic fibrosis patients. <i>Microbiology</i> 156 : 2058-
303	5067.
304	
305	Barker, A.F. (2002) Bronchiectasis. N Engl J Med 246: 1383-1393.
306	
307	Bergamini, G., Di Silvestre, D., Mauri, P., Cigana, C., Bragonzi, A., De Palma, A. et al. (2012) MudPIT
308	analysis of released proteins in Pseudomonas aeruginosa laboratory and clinical strains in relation to
309	pro-inflammatory effects. Integr Biol (Camb) 4: 270-279.
310	
311	Brook, I. (2008) The role of anaerobic bacteria in chronic suppurative otitis media in children:
312	implications for medical therapy. Anaerobe 14: 297-300.
313	
314	Cohen, M., and Sahn, S.A. (1999) Bronchiectasis in systematic diseases. Chest 116: 1063-1074.
315	
316	Ellis D.A., Thornley, P.E., Wightman, A.J., Walker, M., Chalmers, J., and Crofton, J.W. (1981) Present
317	outlook in bronchiectasis: clinical and social study and review of factors influencing prognosis. Thorax
318	36: 659-664.
319	
320	Evans, S.A., Turner, S.M., Bosch, B.J., Hardy, C.C., and Woodhead, M.A. (1996) Lung function in
321	bronciectasis: The influence of Pseudomonas aeruginosa. Eur Respir J 9: 1601-1604.
322	
323	Field, T.R., Sibley, C.D., Parkins, M.D., Rabin, H.R., and Surette, M.G. (2010) The genus Prevotella in
324	cystic fibrosis airways. Anaerobe 16: 337-344.

- Ho, P.L., Chan, K.N., Ip, M.S., Lam, W.K., Ho, C.S., Yuen, K.Y., and Tsang, K.W. (1998) The effect of *Pseudomonas aeruginosa* infection on clinical parameters in steady-state bronchiectasis. *Chest* 114:
 1594-1598.
- 329
- 330 Joish, V.N., Splisbury-Cantalupo, M., Operschall, E., Luong, B., and Boklage, S. (2013) Economic
- 331 burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan
- 332 perspective. Appl Health Econ Health Policy 3: 299-304.
- 333
- 334 Kozlowska, J., Rivett, D.W., Vermeer, L.S., Carroll, M.P., Bruce, K.D., Mason, A.J., and Rogers, G.B.
- 335 (2013) A relationship between Pseudomonal growth behaviour and cystic fibrosis patient lung function
- identified in a metabolomic investigation. *Metabolomics* 9: 1262-1273.
- 337
- 338 Langereis, J.D., and Hermans, P.W. (2013) Novel concepts in nontypeable *Haemophilus influenzae*
- biofilm formation. *FEMS Microbiol Lett* **346**: 81-89.
- 340
- Lopez, A.D., Mathers, C.D., Ezzati, M., Jamison, D.T., and Murray, C.J.L. (2006) Global burden of
 disease and risk factors. USA: Oxford University Press.
- 343
- 344 Ma, L., Wang, S., Wang, D., Parsek, M.R., and Wozniak, D.J. (2012) The roles of biofilm matrix
- polysaccharide PsI in mucoid *Pseudomonas aeruginosa* biofilms. *FEMS Immunol Med Microbiol* 65:
 346 377-380.
- 347
- 348 Martínez-García, M.A., Soler-Cataluña, J.J., Perpiñá-Tordera, M., Román-Sánchez, P., and Soriano,
- 349 J. (2007) Factors associated with lung function decline in adult patients with stable non-cystic fibrosis
- 350 bronchiectasis. *Chest* **132**: 1565-1572.

- 352 Nelson, A., De Soyza, A., Perry, J.D., Sutcliffe, I.C., and Cummings, S.P. (2013) Polymicrobial
- 353 challenges to Koch's postulates: Ecological lessons from the bacterial vaginosis and cystic fibrosis
- 354 microbiomes. Innate Immun 18: 774-783.

- 356 Rogers, G.B., Hoffman, L.R., Carroll, M.P., and Bruce, K.D. (2013a) Interpreting infective microbiota:
- 357 the importance of an ecological perspective. *Trends Microbiol* **21**: 271-276.

- 359 Rogers, G.B., Hart, C.A., Mason, J.R., Hughes, M., Walshaw, M.J., and Bruce, K.D. (2003) Bacterial
- 360 diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length
- heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling. *J Clin Microbiol* 41: 3548-3558.
- 363
- Rogers, G.B., Carroll, M.P., Serisier, D.J., Hockey, P.M., Jones, G., and Bruce, K.D. (2004)
- 365 Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16S
- 366 ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 42: 5176-
- 367 5183.
- 368
- Rogers, G.B., van der Gast, C.J., Cuthbertson, L., Thomson, S.K., Bruce, K.D., Martin, M.L., and
 Serisier, D.J. (2013b) Clinical measures of disease in adult non-CF bronchiectasis correlate with
- airway microbiota composition. *Thorax* **68**: 731-737.
- 372
- 373 Rogers, G.B., Zain, N.M.M., Bruce, K.D., Burr, L.D., Chen, A.C., Rivett, D.W. et al. (2014) A novel
- 374 microbiota stratification system predicts future exacerbations in bronchiectasis. Ann Am Thorac Soc
- 375 Online early doi:10.1513/AnnalsATS.201310-335OC.
- 376
- 377 Rogers, G.B., Cuthbertson, L., Hoffman, L.R., Wing, P.A.C., Pope, C., Hooftman, D.A.P. et al. (2013c)
- Towards unbiased bacterial community analysis in lower respiratory infections. *ISME J* **7**: 697-706.
- 379
- 380 Sadikot, R.T., Blackwell, T.S., Christman, J.W., Prince, A.S. Pathogen-host interactions in
- 381 Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med. 2005 171: 1209-23.

382

- 383 Schobert, M., and Jahn, D. (2010) Anaerobic physiology of Pseudomonas aeruginosa in the cystic
- 384 fibrosis lung. Int J Med Microbiol 300: 549-556.

- Seitz, A.E., Olivier, K.N., Steiner, C.A., Montes de Oca, R., Holland, S.M., and Prevots, D.R. (2010)
 Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. *Chest* 138: 944-949.
- 389
- Serisier, D.J., Martin, M.L. (2011) Long-term, low-dose erythromycin in bronchiectasis subjects with
 frequent infective exacerbations. *Respir Med* **105**: 946-949.
- 392
- 393 Serisier, D.J., Bilton, D., De Soyza, A., Thompson, P.J., Kolbe, J., Greville, H.W. et al (2013a) Inhaled,
- 394 dual-release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised,
- double-blind, placebo-controlled trial. Thorax 68: 812-817.
- 396
- 397 Serisier, D.J. (2012) Inhaled antibiotics for lower respiratory tract infection focus on ciprofloxacin.
- 398 Drugs Today 48: 339-351.
- 399
- 400 Serisier, D.J. (2013b) Risks of population antimicrobial resistance with chronic macrolide use for
- 401 inflammatory airways dieases. Lancet Respir Med 1: 262-274.
- 402
- 403 Serisier, D.J., Martin, M.L., McGuckin, M.A., Lourie, R., Chen, A.C., Brain, B. et al. (2013c) Effect of
- 404 long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis

405 bronchiectasis: the BLESS randomized controlled trial. JAMA 309: 1260-1267.

- 406
- 407 Shoemark, A., Ozerovitch, L., and Wilson, R. (2007) Aetiology in adult patients with bronchiectasis.
- 408 *Respir Med* **101:** 1163-1170.
- 409
- 410 Stressmann, F.A., Rogers, G.B., van der Gast, C.J., Marsh, P., Vermeer, L.S., Carroll, M.P. et al.
- 411 (2012) Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial
- 412 communities infecting the adult cystic fibrosis lung show stability and resilience. *Thorax* **67**: 867-873.

414	Su, S., and Hassett, D.J. (2012) Anaerobic Pseudomonas aeruginosa and other obligately anaerobic
415	bacterial biofilms growing in the thick airway mucus of chronically infected cystic fibrosis patients: an
416	emerging paradigm or "Old Hat"? Expert Opin Ther Targets 16: 859-873.
417	
418	Tashiro, Y., Yawata, Y., Toyofuku, M., Uchiyama, H., and Nomura, N. (2013) Interspecies interaction
419	between Pseudomonas aeruginosa and other microorganisms. Microbes Environ 28: 13-24.
420	
421	Tunney, M.M., Einarsson, G.G., Wei, L., Drain, M., Klem, E.R., Cardwell, C. et al. (2013) Lung
422	microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during
423	exacerbation. Am J Respir Crit Care Med 187: 1118-1126.
424	
425	Tunney, M.M., Field, T.R., Moriarty, T.F., Patrick, S., Doering, G., Muhlebach, M.S. et al. (2008)
426	Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J
427	Respir Crit Care Med 177: 995-1001.
428	
429	van der Gast, C.J., Walker, A.W., Stressmann, F.A., Rogers, G.B., Scott, P., Daniels, T.W. et al.
430	(2011) Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities. ISME
431	J 5: 780-791.
432	
433	van der Gast, C.J., Cuthbertson, L., Rogers, G.B., Pope, C., Marsh, R.L., Redding, G.J. et al. (2014)
434	Three clinically distinct chronic pediatric airway infections share a common core microbiota. Ann Am
435	Thorac Soc Online early doi:10.1513/AnnalsATS.201312-456OC.
436	
437	Visser, S., Martin, M.L., Serisier, D.J. (2012) Improvements in cystic fibrosis lung disease and airway
438	inflammation associated with etanercept therapy for cystic fibrosis: a case report. Lung 190: 579-581.
439	
440	Weycker, D., Edelsberg, J., Oster, G., and Tino, G. (2005) Prevalence and economic burden of
441	bronchiectasis. Clin Pulm Med 12: 205-209.

443 Figure legends

Fig. 1. Relative percentage abundances of *P. aeruginosa* (green circles) and *H. influenzae* (blue) in
samples from within *P. aeruginosa*- and *H. influenzae*-dominated groups (P1-P26 and H1-H34,
respectively).

447

448 Fig. 2. Canonical correspondence biplots for microbiota (a) with and (b) without Pseudomonas and 449 Haemophilus included. Dots represent microbiota samples from the Pseudomonas (denoted with 450 green filled circles) and Haemophilus (blue filled squares) groups. In each instance, the 95 % 451 concentration ellipses are given for the *Pseudomonas* (green) and *Haemophilus* (blue) groups. Biplot 452 lines for the clinical variables included in the analyses show the direction of increase for each variable, 453 and the length of each line indicates the degree of correlation with the ordination axes. CCA field 454 labels: "AH" – antihypertensive, "LABA/ICS" – long acting β -agonist, "SABA" – short acting β -agonist, 455 "prior IE" – number of pulmonary exacerbations in the prior twelve months. Percentage of community 456 variation explained by each axis is given in parentheses.


457


458 Fig. 3. Distribution and dispersal of bacterial taxa among Haemophilus- and Pseudomonas-dominated 459 microbiota samples. (a & b) The number of samples for which each detected bacterial taxon (open 460 circles) was observed, plotted against the abundance (log₁₀ scale) of that species among all samples 461 within each group ((a) Haemophilus group, $r^2 = 0.27$, $F_{1.92} = 33.2$, P < 0.0001; and (b) Pseudomonas 462 group, $r^2 = 0.33$, $F_{1,68} = 33.5$, P < 0.0001). Also given are dispersal plots to identify which bacterial taxa 463 are randomly distributed within the (c) Haemophilus and (d) Pseudomonas groups; a measure used to 464 assign core versus satellite status. Index of dispersion was calculated as the ratio of variance to mean 465 of abundance for each taxon within each group and plotted for each sample. The line depicts the 2.5 466 % confidence limit for the χ^2 distribution. Taxa that fall below this line are randomly distributed and 467 were considered satellite taxa, whereas those that are above the line are non-randomly distributed 468 and were considered core taxa. The 97.5 % confidence limit was not plotted, as no taxon fell below 469 that line.


470

471 Fig. 4. Canonical correspondence biplots for core microbiota (a) with and (b) without *Pseudomonas*472 and *Haemophilus* included. Dots represent core microbiota from the *Pseudomonas* (denoted with

473 green filled circles) and *Haemophilus* (blue filled squares) groups. In each instance, the 95 % 474 concentration ellipses are given for the *Pseudomonas* (green) and *Haemophilus* (blue) groups. Biplot 475 lines for the clinical variables included in the analyses show the direction of increase for each variable, 476 and the length of each line indicates the degree of correlation with the ordination axes. CCA field 477 labels: "AH" - antihypertensive, "LCS" – Leicester cough score, "prior IE" – number of pulmonary 478 exacerbations in the prior twelve months. Percentage of community variation explained by each axis is 479 given in parentheses.










Table 1. Clinical, treatment and comorbidity data for patient population. FEV₁%* – forced expiratory volume in one second, expressed as a percentage of predicted and measured following administration of a bronchodilator; SGRQ, St George's Respiratory Questionnaire – range 1-100, lower scores indicate better quality of life. Leicester cough score – lower scores indicate worse cough symptoms.

	P. aeruginosa		H. influenzae	
Gender (male:female)	6:20		16:18	
Clinical measures of disease	Range	Mean (± SD)	Range	Mean (± SD)
FEV1%*	30.7-94.2	60.5 (± 18.1)	37.2-114.7	71.2 (± 15.1)
Duration of bronchiectasis (years) Pulmonary exacerbations in prior	1-70	45.4 (± 19.6)	10-65	45.4 (± 17.5)
12 months	2-12	6.3 (± 3.0)	2-7	3.4 (± 1.3)
Leicester cough score	5.5-20.2	14.8 (± 3.5)	7.7-19.9	15.6 (± 2.6)
SGRQ total	8.6-79.6	39.9 (± 16.6)	14.9-58.9	36.7 (± 14.0)
Six minute walk test	291-650	488.7 (± 85.1)	275-710	519.6 (± 101.6)
C-reactive protein (mg/litre)	0-21	6.8 (± 6.0)	0-19	7.1 (± 6.1)
Induced sputum IL-8 (ng/ml)	27.4-1053.8	337.6 (± 340.3)	28.8-1326.7	275.2 (± 295.7)
Induced sputum IL-1β (ng/ml)	0.25-36.2	9.8 (± 10.7)	0.6-115.8	11.4 (± 22.3)
Treatment		· · ·		, , , , , , , , , , , , , , , , , , ,
Short acting β-agonist	14		10	
Inhaled corticosteroid	16		17	
Inhaled corticosteroid + long				
acting β-agonist	13		10	
Anti-cholinergics	6		2	
Aspirin	3		9	
Beta blocker	0		3	
Nasal steroids	2		4	
Prednisolone	3		1	
Antihypertensive	9		16	
Comorbidity				
Cerebrovascular disease	1		4	
Heart disease	2		4	
Hypertension	6		14	
Diabetes	1		0	

Table 2. Similarity of percentages (SIMPER) analysis of bacterial community dissimilarity (Bray-Curtis) between core taxa groups without *Pseudomonas* and *Haemophilus*. Given is mean % abundance of sequences for each taxon across the samples they were observed to occupy. Analysis was based on an average of 10647 sequences per sample (SD 5070, range 2395-28916). Also given is the average dissimilarity between samples (overall mean = 61.9%). Percentage contribution is the mean contribution divided by mean dissimilarity across samples. SIMPER analysis with *Pseudomonas* and *Haemophilus* is presented in Table S1.

	% Mean abundance		Sample	s detected in			
Taxon	Pseudomonas group	Haemophilus group	<i>Pseudomonas</i> group	<i>Haemophilus</i> group	Average dissimilarity	% Contribution	Cumulative %
Prevotella	31.9	31	23	27	14.96	24.17	24.17
Veillonella	20.8	26.7	25	30	11.85	19.14	43.31
Streptococcus	13.2	18.3	22	26	10.51	16.99	60.30
Moraxella	14	4.9	10	5	8.69	14.04	74.34
Neisseria	7.8	13.6	18	25	7.59	12.26	86.60
Flavobacterium	8.7	0	17	0	4.35	7.02	93.62
Leptotrichia	3.6	2.0	16	18	2.22	3.59	97.21
Fusobacterium	0	3.5	0	11	1.72	2.79	100

Table 3. Canonical correspondence analyses for determination of percent variation in lung microbiota from bronchiectasis subjects by clinical variables. LABA, long acting β -agonist; ICS, inhaled corticosteroid; SABA, short acting β -agonist.

			Whole microbiota without P &				Core microbiota without P &		
	Whole microbiota		Н		Core microbiota		Н		
	% of	Probabilit			% of	Probabilit			
Variable	variance	у	% of variance	Probability	variance	у	% of variance	Probability	
Prior Exacerbations	11.35	0.01	2.35	0.02	13.8	0.01	2.7	0.01	
FEV ₁ % predicted	4.60	0.01	2.41	0.01	5.5	0.01	4.9	0.01	
Hypertension	3.08	0.01	-	-	3.5	0.01	2.7	0.01	
Gender	3.01	0.01	-	-	3.4	0.01	-	-	
Anti-Hypertensive	-	-	2.20	0.01	-	-	2.3	0.01	
LABA + ICS	-	-	1.81	0.02	-	-	-	-	
SABA	-	-	1.54	0.02	-	-	-	-	
Leicester cough									
score	-	-	-	-	-	-	3.1	0.02	

Table S1. Similarity of percentages (SIMPER) analysis of bacterial community dissimilarity (Bray-Curtis) between core taxa groups with *Pseudomonas* and *Haemophilus*. Given is mean % abundance of sequences for each taxon across the samples they were observed to occupy. Analysis was based on an average of 10647 sequences per sample (SD 5070, range 2395-28916). Also given is the average dissimilarity between samples (overall mean = 61.9%). Percentage contribution is the mean contribution divided by mean dissimilarity across samples.

	% Mean abundance		Sample	s detected in			
Taxon	<i>Pseudomonas</i> group	<i>Haemophilus</i> group	<i>Pseudomonas</i> group	<i>Haemophilus</i> group	Average dissimilarity	% Contribution	Cumulative %
Pseudomonas	87.3	0.37	26	22	44.44	45.53	45.53
Haemophilus	0.56	86	24	34	43.93	45.01	90.54
Prevotella	2.61	4.14	23	27	2.51	2.57	93.11
Streptococcus	1.51	2.35	22	26	1.69	1.73	94.84
Veillonella	1.44	2.8	25	30	1.67	1.71	96.55
Flavobacterium	2.38	0	17	0	1.21	1.24	97.79
Moraxella	1.18	0.54	10	5	0.83	0.85	98.65
Neisseria	0.74	0.97	18	25	0.74	0.75	99.40
Leptotrichia	0.57	0.20	16	18	0.35	0.36	99.77
, Fusobacterium	0	0.45	0	11	0.23	0.23	100

1 Supplementary Methods

2 Samples were collected from participants in the Bronchiectasis and Low-dosen Erythromycin Study 3 (BLESS) trial (Serisier et al., 2013). Adult patients aged 20 to 85 years were eligible if they had 4 bronchiectasis documented by high-resolution computed tomographic scan, at least 2 separate 5 pulmonary exacerbations requiring supplemental systemic antibiotic therapy in the preceding 12 6 months, and daily sputum production. Participants were required to have been clinically stable for at 7 least 4 weeks prior to enrolment (defined as no symptoms of exacerbation, no requirement for 8 supplemental antibiotic therapy, and forced expiratory volume in the firs second of expiration [FEV₁] 9 within 10% of best recently recorded value where available). Exclusion criteria included CF, current 10 mycobacterial disease or bronchopulmonary aspergillosis, any reversible cause for exacerbations, 11 maintenance oral antibiotic prophylaxis, prior macrolide use except short-term, changes to 12 medications in the preceding 4 weeks, cigarette smoking within 6 months, and medications or 13 comorbidities with the potential for important interactions with erythromycin. All participants required 14 negative results from sputum mycobacterial cultures prior to randomization. The study was approved 15 by the Mater Health Service human research ethics committee, and all participants provided written, 16 informed consent.

17

18 Sample collection

19 Subjects were instructed to perform their usual chest physiotherapy regime on the morning of the 20 sputum induction procedure. Prior to commencement of hypertonic saline inhalation, any spontaneous 21 sputum expectorated was collected for standard culture. Sputum induction (SI) was performed after 22 inhalation of 400 ug of albuterol, using 4.5% hypertonic saline nebulised from an ultrasonic nebuliser 23 (output >1 mL/ min) for 20 minutes in 4 periods of 5 minutes each, according to the standardised 24 protocol recommended by the European Respiratory Society taskforce [Paggiaro et al., 2002] 25 Following mouth-rinsing and expectoration, sputum was collected following each nebulisation period, 26 on each occasion preceded immediately by spirometry. The first sputum sample was refrigerated 27 immediately following collection and frozen at -80 °C within an hour. A cold chain was maintained up 28 until the point of DNA extraction.

29

30 DNA extraction protocol

1 Nucleic acid extractions were performed on 500 µL cell suspensions. Guanidinium thiocyanate-2 EDTA-sarkosyl (500 µL) and PBS (500 µL), pH 8.0, were added to samples. Cell disruption was 3 achieved using a Fastprep-24 Instrument (MP Biomedicals Europe, Illkirch, France) 6.5 m/s, 60 s, 4 followed by incubation at 90 °C for 1 min and -20 °C for 5 min. Cell debris was pelleted by 5 centrifugation at 12 000 × g for 2 min at 4 °C. Supernatant was transferred to a fresh microfuge tube. 6 NaCl (to a final concentration of 0.5 mol/L and polyethylene glycol (to a final concentration of 15%) 7 were added and DNA precipitated at 4 °C for 30 min. DNA was pelleted by centrifugation at 12 000 × g 8 for 2min at 4 °C and resuspended in 300 µL of sterile distilled water. Samples were heated at 90 °C for 9 30 s and vortexed. Phenol/chloroform (1:1) (300 µL) was added, and samples were vortexed for 20 s 10 before centrifugation at 12 000 × g at 4 °C for 3min. The upper phase was then transferred to a fresh 11 microfuge tube. Total DNA was then precipitated by the addition of an equal volume of isopropanol, a 12 0.1-volume 10 mol/L ammonium acetate, and 1 µL of GenElute linear polyacrylamide (Sigma-Aldrich, 13 Gillingham, UK) and incubated at -20 °C for 25 min. DNA was pelleted by centrifugation at 12 000 × g 14 at 4 °C for 5 min. Pelleted DNA was then washed 3 times in 70% ethanol, dried, and resuspended in 15 50 µL of sterile distilled water. DNA extracts were guantified using the Picodrop Microlitre 16 Spectrophotometer (GRI, Braintree, UK). Negative controls, consisting of sterile water, were included 17 in the PMA treatment, DNA extraction, and PCR amplification steps.

18

19 Pyrosequencing

20 Bacterial tag-encoded FLX amplicon pyrosequencing (bTEFAP) was performed as described 21 previously Gray28F 5'-TTTGATCNTGGCTCAG-3' Gray519r 5'using and 22 GTNTTACNGCGGCKGCTG-3'). Initial generation of the sequencing library involved a one-step PCR 23 of 30 cycles, using a mixture of Hot Start and HotStar high fidelity Tag DNA polymerase, as described 24 previously (4). Tag-encoded FLX amplicon pyrosequencing analyses utilized Roche 454 FLX 25 instrument with Titanium reagents, titanium procedures performed at the Research and Testing 26 Laboratory (Lubbock, TX) using RTL protocols (www.researchandtesting.com).

Following sequencing, all failed sequence reads, low quality sequence ends and tags and primers were removed. Sequences with ambiguous base calls, sequences with homopolymers > 6bp were removed. Further, any non-bacterial ribosomal sequences and chimeras using B2C2 (Dowd *et al.*, 30 2008) as described previously (Dowd *et al.*, 2008). To determine the identity of bacterial species in the

remaining sequences, sequences were de-noised, assembled into OUT clusters at 97% identity, and queried using a distributed .NEt algorithm that utilizes Blastn+ (KrakenBLAST www.krakenblast.com) against a database of high quality 16S rRNA gene bacterial sequences. Using a .NET and C# analysis pipeline the resulting BLASTn+ outputs were compiled, data reduction analysis performed, and sequence identity classification carried out, as described previously (Dowd *et al.*, 2008).

6

7 Quantitative PCR

8 P. aeruginosa density was determined using a Tagman assay, in which a 117 bp region between 9 positions 330 to 447 of the P. aeruginosa OprL gene was amplified, as described previously 10 (Feizabadi et al., 2010). Primers (PsF: 5'-CGAGTACAACATGGCTCTGG-3', EubR: 5'-11 ACCGGACGCTCTTTACCATA-3') were used at a concentration of 500 nM each, and the probe 12 (EubPr: 5'-FAM- CCTGCAGCACCAGGTAGCGC -TAMRA-3') at a concentration of 250 nM. All 13 reactions were carried out in a total volume of 20 µl containing primers at a concentration of 500 nM 14 each, probe concentration of 250 nM, 1 µl of template and LightCycler 480 Probes Master (Roche 15 Diagnostics GmbH, Mannheim, Germany) at 1x final concentration. Quantitative PCR assays were 16 carried out using the Rotor-Gene Q (Qiagen, Crawley, UK) with a temperature profile of 95 °C for 5 17 min, followed by 45 cycles at 95 °C for 15 s and 58 °C for 45 s. Nutrient broth culture of P. aeruginosa 18 (NCTC 12934/ATCC 27853) was incubated at 37 °C for 16 h, with cfu/ml estimated by incubation of 19 dilutions (n=4) on Nutrient agar at 37° for 24 h, followed by colony counts. DNA was extracted from 20 tenfold dilutions of the broth culture in the same way as for the sputum samples, and RT-PCR was 21 carried out as above on the DNA extracts. The standard curve generated using P. aeruginosa (gPCR efficiency = 1.20; R^2 value = 0.996) was used as reference to allow direct comparisons to be made by 22 23 the Rotor Gene Q-series Software (Qiagen, Crawley, UK).

24 H. influenzae density was determined using a Tagman assay, in which a 90-bp region between 25 positions 518 to 608 of the H. influenzae Hel gene was amplified, using primers (HelSF: 5'-26 CCGGGTGCGGTAGAATTTAATAA-3', EubR: 5'-CTGATTTTTCAGTGCTGTCTTTGC-3') were used at 27 of 100 nM а concentration each. and the probe (EubPr: 5'-FAM-28 ACAGCCACAACGGTAAAGTGTTCTACG-TAMRA-3') (Long, 2011). All PCR reactions were carried 29 out in a total volume of 20 µl containing primers and probe at a concentration of 1000:500:200 nM 30 (HelSF: HelSR; HelSPr), 1 µl of template and LightCycler 480 Probes Master (Roche Diagnostics

GmbH, Mannheim, Germany) at 1x final concentration. Quantitative PCR assays were carried out using the Rotor-Gene Q (Qiagen, Crawley, UK) with a temperature profile of 95 °C for 5 min, followed by 45 cycles at 95 °C for 15 s and 60 °C for 60 s. A standard curve was generated by qPCR settings as above using *H. influenzae* DNA extract obtained from the Health Protection Agency (*H. influenza* clinical isolate, chronic respiratory infection, 2012). *H. influenza* load (cfu/ml) was determined by direct comparison with the standard curve (qPCR efficiency = 1.05; R^2 value = 0.997) using the Rotor Gene Q-series Software (Qiagen, Crawley, UK).

- 8
- 9 1. Developed in house at the Health Protection Agency London by Dr. Clare Ling, 2011.
- Dowd SE, Wolcott RD, Sun Y, McKeehan T, Smith E, Rhoads D. (2008) Polymicrobial nature
 of chronic diabetic foot ulcer biofilm infections determined using bacterial tag encoded FLX
 amplicon pyrosequencing (bTEFAP). PLOS One 3:e3326.
- Feizabadi MM, Majnooni A, Nomanpour B, Fatolahzadeh B, Raji N, Delfani S, Habibi M, Asadi
 S, Parvin M. (2010) Direct detection of Pseudomonas aeruginosa from patients with
 healthcare associated pneumonia by real time PCR. Infect Genet Evol 10:1247–51.
- Paggiaro PL, Chanez P, Holz O, Paggiaro PL1, Chanez P, Holz O, Ind PW, Djukanović R,
 Maestrelli P, Sterk PJ. (2002) Sputum induction. Eur Respir J 20:Suppl 37, 3s-8s. x
- 18 5. Serisier, D.J., Martin, M.L., McGuckin, M.A., Lourie, R., Chen, A.C., Brain, B. Biga S,
- 19 Schlebusch S, Dash P, Bowler SD. (2013) Effect of long-term, low-dose erythromycin on
- 20 pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS
- 21 randomized controlled trial. JAMA 309: 1260-1267.